Sugi Predict

Sugi Predict / Compounds / SCHEMBL7378277

SCHEMBL7378277

SCHEMBL7378277

CCOC(=O)c1cc2c(cn1)[nH]c1ccc(Br)cc12

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA1 P14867 13/20 0.74
▸ GABRG2 P18507 13/20 0.74
▸ GABRB3 P28472 13/20 0.74
▸ GABRA5 P31644 13/20 0.74
▸ GABRA3 P34903 13/20 0.74
▸ GABRA2 P47869 13/20 0.74
▸ GABRA4 P48169 11/20 0.74
▸ GABRA6 Q16445 11/20 0.74
▸ GABRP O00591 6/20 0.73
▸ GABRD O14764 6/20 0.73
▸ GABRB1 P18505 6/20 0.73
▸ GABRB2 P47870 6/20 0.73
▸ GABRE P78334 6/20 0.73
▸ GABRG1 Q8N1C3 6/20 0.73
▸ GABRG3 Q99928 6/20 0.73
▸ GABRQ Q9UN88 6/20 0.73
▸ ALDH1A1 P00352 4/20 0.73
▸ MAPT P10636 4/20 0.73
▸ SMN1; SMN2 Q16637 3/20 0.73
▸ KDM4E B2RXH2 3/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10740909 0.87 GABRA1 (0.77) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL7382523 0.86 GABRA1 (0.76) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL10417476 0.86 GABRA1 (0.76) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL7375694 0.85 GABRA1 (0.74) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL7380021 0.85 GABRA1 (1.00) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL7378899 0.85 GABRA1 (0.74) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL6222870 0.85 GABRA1 (0.74) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL601711 0.85 GABRA1 (1.00) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL29672619 0.85 GABRA1 (1.00) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL30274389 0.85 GABRA1 (1.00) GABRA1GABRG2GABRB3GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2925129-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2015-10-07 — — EP claimed
WO-2014031125-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-02-27 — — WO claimed
US-20130040977-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2013-02-14 — — US claimed
US-20190218203-A1 Neuroprotective Compounds and Use Thereof UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2019-07-18 — — US disclosed
US-20190135809-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-05-09 — — US disclosed
US-10183011-B2 Anti-depression compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-01-22 — — US disclosed
US-10183011-B2 Anti-depression compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-01-22 — — US disclosed
US-20180318255-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2018-11-08 — — US disclosed
US-9962368-B2 Pro-neurogenic compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-05-08 — — US disclosed
US-9962368-B2 Pro-neurogenic compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-05-08 — — US disclosed
US-9962368-B2 Pro-neurogenic compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-05-08 — — US disclosed
US-20130040977-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2013-02-14 — — US disclosed
US-5010077-A Tranquilizers A/S FERROSAN (DK) 1991-04-23 — — US disclosed
EP-0054507-B1 3-SUBSTITUTED BETA-CARBOLINES, PROCESS FOR THEIR PRODUCTION AND COMPOSITIONS CONTAINING THEM SCHERING AKTIENGESELLSCHAFT (DE) 1988-02-17 — — EP disclosed
US-4596808-A Nervous system disorders SCHERING AKTIENGESELLSCHAFT (DE) 1986-06-24 — — US disclosed
EP-0030254-B1 BETA-CARBOLIN-3-CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR THERAPEUTICAL USE SCHERING AKTIENGESELLSCHAFT (DE) 1984-10-31 — — EP disclosed
US-4435403-A TRANQUILIZERS SCHERING AKTIENGESELLSCHAFT (DE) 1984-03-06 — — US disclosed
US-4371536-A TRANQUILIZERS A/S FERROSAN (DK) 1983-02-01 — — US disclosed
EP-0054507-A2 3-Substituted beta-carbolines, process for their production and compositions containing them SCHERING AKTIENGESELLSCHAFT (DE) 1982-06-23 — — EP disclosed
EP-0030254-A1 Beta-carbolin-3-carboxylic acid derivatives, pharmaceutical compositions containing them and their therapeutical use SCHERING AKTIENGESELLSCHAFT (DE) 1981-06-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218203-A1 Neuroprotective Compounds and Use Thereof NLN, GAP43, BDNF GABRA1 1871/4885GABRG2 1885/4885GABRB3 442/4885
US-20180318255-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX GABRA1 1539/4885GABRG2 1270/4885GABRB3 387/4885
US-10183011-B2 Anti-depression compounds BDNF, DCX, GAP43 GABRA1 1382/4885GABRG2 1165/4885GABRB3 403/4885
US-20190135809-A1 Pro-Neurogenic Compounds BDNF, NES, DCX GABRA1 1457/4885GABRG2 1218/4885GABRB3 347/4885
US-20130040977-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX GABRA1 1539/4885GABRG2 1270/4885GABRB3 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.